(SENS) Senseonics Holdings, Common - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE MKT (USA) | Market Cap: 331m USD | Total Return: -40.5% in 12m

Implantable Sensors, Smart Transmitters, Monitoring Apps, Glucose Monitors
Total Rating 22
Safety 23
Buy Signal -0.12
Medical Devices
Industry Rotation: +5.3
Market Cap: 331M
Avg Turnover: 3.78M
Risk 3d forecast
Volatility91.2%
VaR 5th Pctl14.3%
VaR vs Median-5.02%
Reward TTM
Sharpe Ratio-0.32
Rel. Str. IBD8.1
Rel. Str. Peer Group23.9
Character TTM
Beta1.157
Beta Downside1.809
Hurst Exponent0.497
Drawdowns 3y
Max DD80.92%
CAGR/Max DD-0.28
CAGR/Mean DD-0.41
EPS (Earnings per Share) EPS (Earnings per Share) of SENS over the last years for every Quarter: "2021-03": -0.68, "2021-06": -0.42, "2021-09": 0.08, "2021-12": 0.21, "2022-03": -0.03, "2022-06": -0.03, "2022-09": -0.13, "2022-12": 0.02, "2023-03": -0.04, "2023-06": -0.04, "2023-09": -0.04, "2023-12": -0.03, "2024-03": -0.03, "2024-06": -0.03, "2024-09": -0.04, "2024-12": -0.02, "2025-03": -0.02, "2025-06": -0.4, "2025-09": -0.43, "2025-12": -0.46, "2026-03": -0.71,
Last SUE: -0.04
Qual. Beats: 0
Revenue Revenue of SENS over the last years for every Quarter: 2021-03: 2.846, 2021-06: 3.289, 2021-09: 3.532, 2021-12: 4.008, 2022-03: 2.481, 2022-06: 3.714, 2022-09: 4.622, 2022-12: 5.571, 2023-03: 4.137, 2023-06: 4.126, 2023-09: 6.097, 2023-12: 8.03, 2024-03: 5.047, 2024-06: 4.865, 2024-09: 4.263, 2024-12: 8.297, 2025-03: 6.257, 2025-06: 6.649, 2025-09: 8.095, 2025-12: 14.256, 2026-03: 11.711,
Rev. CAGR: 25.31%
Rev. Trend: 89.2%
Last SUE: 4.00
Qual. Beats: 1

Warnings

Share dilution 27.5% YoY

Interest Coverage Ratio -17.6 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Tailwinds

Confidence

Description: SENS Senseonics Holdings, Common

Senseonics Holdings, Inc. is a medical technology firm specializing in the design and manufacturing of implantable continuous glucose monitoring (CGM) systems. Its primary product line, branded under the Eversense name, utilizes a subcutaneous sensor paired with a removable smart transmitter to provide real-time glucose data via a mobile application. Headquartered in Germantown, Maryland, the company distributes its long-term monitoring solutions through a network of healthcare providers and strategic fulfillment partners.

The company operates within the high-growth diabetes management sector, where the shift from traditional finger-stick testing to automated CGM technology is a primary industry driver. Unlike traditional CGMs that require weekly or bi-weekly sensor replacements, Senseonics utilizes a differentiated business model focused on long-term implantable sensors designed to last several months, reducing the frequency of hardware changes for the patient. You may find additional data points regarding its market positioning by reviewing the latest reports on ValueRay.

Headlines to Watch Out For
  • FDA approval and launch of Eversense 365 expands addressable patient population
  • Strategic partnership with Ascensia Diabetes Care dictates global commercial distribution success
  • Insurance coverage expansion and payer reimbursement rates drive domestic revenue growth
  • Development of integrated insulin pump compatibility influences long-term competitive positioning
  • High research and development spending necessitates future capital raises or dilution
Piotroski VR-10 (Strict) 2.0
Net Income: -87.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.74 > 0.02 and ΔFCF/TA 2.75 > 1.0
NWC/Revenue: 162.0% < 20% (prev 282.9%; Δ -120.9% < -1%)
CFO/TA -0.73 > 3% & CFO -75.1m > Net Income -87.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.51 > 1.5 & < 3
Outstanding Shares: last quarter (45.8m) vs 12m ago 27.48% < -2%
Gross Margin: 52.07% > 18% (prev 0.07%; Δ 5.20k% > 0.5%)
Asset Turnover: 42.84% > 50% (prev 27.15%; Δ 15.68% > 0%)
Interest Coverage Ratio: -17.64 > 6 (EBITDA TTM -81.5m / Interest Expense TTM 4.71m)
Altman Z'' -15.00
A: 0.64 (Total Current Assets 92.3m - Total Current Liabilities 26.3m) / Total Assets 102.9m
B: -10.20 (Retained Earnings -1.05b / Total Assets 102.9m)
C: -0.88 (EBIT TTM -83.2m / Avg Total Assets 95.0m)
D: -15.31 (Book Value of Equity -1.05b / Total Liabilities 68.5m)
Altman-Z'' = -51.01 = D
Beneish M -3.57
DSRI: 1.39 (Receivables 15.1m/6.32m, Revenue 40.7m/23.7m)
GMI: 0.14 (GM 52.07% / 7.19%)
AQI: 0.21 (AQ_t 0.01 / AQ_t-1 0.06)
SGI: 1.72 (Revenue 40.7m / 23.7m)
TATA: -0.12 (NI -87.2m - CFO -75.1m) / TA 102.9m)
Beneish M = -3.57 (Cap -4..+1) = AAA
What is the price of SENS shares?

As of May 27, 2026, the stock is trading at USD 6.43 with a total of 497,926 shares traded.
Over the past week, the price has changed by +15.65%, over one month by -11.55%, over three months by -22.99% and over the past year by -40.46%.

Is SENS a buy, sell or hold?

Senseonics Holdings, Common has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold SENS.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 1
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the SENS price?
Analysts Target Price 17.4 170.9%
Senseonics Holdings, Common (SENS) - Fundamental Data Overview as of 25 May 2026
Market Cap USD = 331.0m (331.0m USD * 1.0 USD.USD)
P/E Forward = 21.0084
P/S = 8.1297
P/B = 9.6241
Revenue TTM = 40.7m USD
EBIT TTM = -83.2m USD
EBITDA TTM = -81.5m USD
Long Term Debt = 35.9m USD (from longTermDebt, last quarter)
Short Term Debt = 944k USD (from shortTermDebt, last quarter)
Debt = 50.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.23m
Net Debt = -14.3m USD (calculated: Debt 50.4m - CCE 64.6m)
Enterprise Value = 316.7m USD (331.0m + Debt 50.4m - CCE 64.6m)
Interest Coverage Ratio = -17.64 (Ebit TTM -83.2m / Interest Expense TTM 4.71m)
EV/FCF = -4.17x (Enterprise Value 316.7m / FCF TTM -75.9m)
FCF Yield = -23.97% (FCF TTM -75.9m / Enterprise Value 316.7m)
 FCF Margin = -186.5% (FCF TTM -75.9m / Revenue TTM 40.7m)
 Net Margin = -214.2% (Net Income TTM -87.2m / Revenue TTM 40.7m)
 Gross Margin = 52.07% ((Revenue TTM 40.7m - Cost of Revenue TTM 19.5m) / Revenue TTM)
Gross Margin QoQ = 59.26% (prev 53.79%)
Tobins Q-Ratio = 3.08 (Enterprise Value 316.7m / Total Assets 102.9m)
Interest Expense / Debt = 9.36% (Interest Expense 4.71m / Debt 50.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -65.7m (EBIT -83.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.13 (Total Current Assets 92.3m / Total Current Liabilities 29.5m)
Debt / Equity = 1.47 (Debt 50.4m / totalStockholderEquity, last quarter 34.3m)
 Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -14.3m / EBITDA -81.5m)
 Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -14.3m / FCF TTM -75.9m)
 Total Stockholder Equity = 67.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -91.74% (Net Income -87.2m / Total Assets 102.9m)
RoE = -7.81% (Net Income TTM -87.2m / Total Stockholder Equity 1.12b)
RoCE = -7.22% (EBIT -83.2m / Capital Employed (Equity 1.12b + L.T.Debt 35.9m))
 RoIC = -511.8% (out of range, set to none) (NOPAT -65.7m / Invested Capital 12.8m)
 WACC = 9.70% (E(331.0m)/V(381.3m) * Re(10.05%) + D(50.4m)/V(381.3m) * Rd(9.36%) * (1-Tc(0.21)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 27.52%
 [DCF] Fair Price = unknown (Cash Flow -75.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 89.18 | Revenue CAGR: 25.31% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.63 | Chg30d=+12.77% | Revisions=+40% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.61 | Chg30d=+16.09% | Revisions=+60% | Analysts=6
EPS current Year (2026-12-31): EPS=-2.49 | Chg30d=+13.24% | Revisions=+64% | GrowthEPS=-50.0% | GrowthRev=+76.4%
EPS next Year (2027-12-31): EPS=-2.27 | Chg30d=+13.92% | Revisions=+45% | GrowthEPS=+8.9% | GrowthRev=+57.5%
[Analyst] Revisions Ratio: +64%